FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesFacilitator Training Video
Topic: Conference
Conference Training
Members
GCSG Presentation Tips from Steve Jacobs
Topics: Communication, Personal Development
Conference Training
Members
COVID-19 and the Clinical Supply Chain: Mitigating Risk and Maintaining Business Continuity
Topics: COVID-19, Pharma Industry, Supply Chain
Position Paper
Free
